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Abstract
The 2,4′- and 4,4′-linked variants of the cytotoxic agent secalonic acid A and their analogues have 
been synthesized. Kinetic resolution of an unprotected tetrahydroxanthone scaffold followed by 
copper-mediated biaryl coupling allowed for efficient access to these compounds. Evaluation of 
the “shapeshifting” properties of 2,2′-, 2,4′-, and 4,4′-linked variants of the secalonic acids A in a 
polar solvent in conjunction with assays of the compounds against select cancer cell lines was 
conducted to study possible correlations between linkage variation and cytotoxicity.
INTRODUCTION
Dimeric tetrahydroxanthone natural products belong to a family of secondary metabolite 
mycotoxins.1 Their interesting biological properties and varied structures have attracted 
significant attention from both the biological and the chemical communities. Among these 
natural products, the secalonic acids, 2,2′-linked dimeric tetrahydroxanthones,2 were found 
to exhibit interesting bioactivities. For instance, secalonic acid A (1)3 has antitumor activity 
and also reduces colchicine toxicity in rat cortical neurons.4 In addition to the 2,2′-linked 
dimeric natural products, 2,4′- and 4,4′-linked secalonic acids are also found in nature. For 
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example, the 2,4′-linked isomer penicillixanthone A (2)5 and the 4,4′-linked secalonic acid E 
(talaroxanthone, 4)6 have recently been isolated and characterized (Figure 1). In addition to 
the secalonic acids, biaryl linkage variation has been observed in related natural products. 
Recently, a related subclass of tetrahydroxanthones, phomoxanthones (5), has been isolated 
and characterized.7 The presence of a 4,4′ linkage was established by X-ray crystallography. 
The corresponding 2,2′-linked dimer dicerandrol C (6)8 and 2,4′-linked dimer 
phomoxanthone B (7) have also been isolated from natural sources.
Because of the presence of varied biaryl linkages, the shape of molecules may change 
dramatically, which may have a substantial influence on their biological properties. For 
example, the 4,4′-linked compound phomoxanthone A exhibits a strong cytotoxicity to 
L5178Y cancer cells (IC50 = 0.3 µM),7c whereas the 2,2′-linked congener dicerandrol C was 
found to be somewhat less potent (IC50 = 2.8 µM).8c For the secalonic acids, previous 
studies indicated that the linkage may undergo facile isomerization in polar solvents.9 A 
similar transformation was observed for the monomeric tetrahydroxanthone parnafungins to 
generate a mixture of isomers A1 (8)/A2 (9)/B1 (10)/B2 (11) from each pure isomer at room 
temperature (Figure 2).10 The authors propose that retro-oxa-Michael reaction of the 
tetrahydroxanthone to acetophenone intermediates 12/13 was responsible for linkage 
isomerization. Interestingly, it was determined by affinity-selection/mass spectrometry (AS–
MS) that parnafungin A1 (8) was the active inhibitor of the fungal enzyme polyadenosine 
polymerase (PAP).11 The fluxional properties of the tetrahydroxanthone scaffold can be 
compared to those of other natural products such as coleophomones12 and the 
“shapeshifting” bullvallene system reported by Bode and co-workers.13
Because of their interesting chemical and biological properties, tetrahydroxanthones have 
drawn attention from synthetic organic chemists. Recently, our laboratory14 as well as the 
laboratories of Bräse,15 Nicolaou,16 Tietze,17 and other groups18 have accomplished 
syntheses of monomeric chromone lactones, tetrahydroxanthones, and 2,2′-linked dimeric 
tetrahydroxanthone natural products. We considered that chemical syntheses of 2,4′-linked 
and 4,4′-linked secalonic acids would be not only be synthetically challenging but may 
provide access to dimeric linkage variations to study their “shapeshifting”13 properties of 
this class of compounds. Moreover, along with the previously synthesized 2,2′-linked 
compounds,14 these compounds may be used to ultimately construct a tetrahydroxanthone 
library with potentially interesting biological activities. In this Article, we describe syntheses 
of 2,4′- and 4,4′-linked variants of the cytotoxic agent secalonic acid A and its analogues. 
Evaluation of the “shapeshifting” properties of 2,2′-, 2,4′- and 4,4′-linked secalonic acids A 
in conjunction with assays of the compounds against select cancer cell lines was conducted 
to study preliminary correlations between linkage variation and cytotoxicity.
RESULTS AND DISCUSSION
Synthesis of 4,4′-Linked Chromone Lactone Dimers
In addition to the dimeric tetrahydroxanthones, there have been a number of related 4,4′-
linked chromone lactone dimers isolated from nature, including gonytolide A19 and paecilin 
A.20 On the basis of our strategy for the synthesis of 2,2′-linked chromone lactones,14b we 
anticipated that the corresponding 4,4′-linked dimers may be accessed using our previously 
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developed copper-mediated stannane coupling approach if prefunctionalization of the para-
position of the chromone lactone monomer could be accomplished. However, after 
investigating various iodination and bromination conditions on monomer 14, we found that 
the para-halogenated chromone lactone was generally the minor product. For example, 
treatment of substrate 14 with 1 equiv of NBS led to a mixture of brominated products 15, 
16, and 17 (Scheme 1). Interestingly, use of In(OTf)3 as catalyst21 for the bromination led to 
the production of ortho-bromide 16 in 62% yield along with para isomer 15 (37%). After 
further evaluation of additives, we found that a catalytic amount of AuCl322 significantly 
changed the outcome of the bromination (Scheme 1b). Treatment of 14 with NBS in the 
presence of 5 mol % of AuCl3 favored production of the para-brominated chromone lactone 
15. This phenomenon was also observed in other related chromone lactone substrates.23 To 
understand possible operative mechanisms, chromone lactone 14 was treated with AuCl3 (72 
h) (Scheme 2a) in which case several chlorinated products 19–21 were obtained.24 We 
considered that the Au(III) catalyst may chelate with the lactone and/or methyl ester 
moieties of substrate 14 to direct the bromination, potentially via a direct auration process25 
to generate the chelated gold(III) aryl intermediate 22 (Scheme 2b). This hypothesis is also 
supported by the fact that AuCl3 failed to enhance the yield of the para product on 
tetrahydroxanthone substrates. However, an auration pathway cannot completely explain the 
unselective chlorination observed using AuCl3. As an alternative mechanism, AuCl3 may 
also chelate to the phenol26 of substrate 14 to afford a putative aurate complex 23, which 
may effectively block the ortho-position to bromination with NBS (Scheme 2c). The latter 
mechanism is also supported by 1H NMR experiments involving complexation of substrate 
14 with AuCl3 in which case loss of the phenol resonance of 14 was observed.23 Our current 
results highlight the importance of the chromone lactone ring system in the gold(III)-
catalyzed bromination process.
With the para-bromide 15 in hand, it was smoothly converted to the corresponding para-
stannane 18 in 78% yield (Scheme 1). We next investigated stannane dimerization with 
different metals (e.g., CuCl) and oxidants (e.g., air, O2, CuCl2).14b Surprisingly, phenolic 
stannane 18 did not generate the desired 4,4′-linked dimers under these conditions; the main 
side reaction generally observed was protodestannylation likely due to the low pKa of the 
proximal phenol. Accordingly, we altered our strategy, and compound 14 was O-methylated 
with Me2SO4 (Scheme 3). Treatment of 24 with nBu4NBr3 led to the production of bromide 
25 in 93% yield.27 Subsequent stannylation provided compound 26 in 70% yield. When we 
applied the previously developed CuCl/air-mediated coupling conditions,14b stannane 26 
was only converted to dimeric products in trace amounts with a large amount of the starting 
material remained intact. We thought that use of air as oxidant was difficult to accurately 
control and that this could lead to the variable conversions observed in the reaction. 
Fortunately, use of CuCl2 as oxidant afforded the C2 and Cs dimers 27 and 28 in 
reproducible yields (23%).
Synthesis of 4,4′-Linked Tetrahydroxanthone Dimers
The successful synthesis of 4,4′-linked chromone lactones encouraged us to further 
investigate syntheses of the corresponding 4,4′-linked dimeric tetrahydroxanthones. We 
envisioned that an enantiopure, para-functionalized tetrahydroxanthone could serve as a key 
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intermediate. Our initial thought was that a para-brominated tetrahydroxanthone could be 
obtained from a brominated chromone lactone through Dieckmann cyclization (Scheme 4). 
However, potential linkage isomerization of tetrahydroxanthones could create difficulties in 
this transformation. Accordingly, we treated the orthobrominated chromone lactone 16 with 
10 equiv of NaH in THF for 3 h. In this case, the corresponding tetrahydroxanthone 29 was 
isolated in 43% yield as a single diastereomer. Surprisingly, when we treated the bromide 15 
with 10 equiv of NaH, we obtained three different tetrahydroxanthone products. The desired 
para-brominated tetrahydroxanthone 30 was obtained in only 10% yield. The main 
byproduct observed was the ortho-bromide 31 with an anti-configuration between the 
hydroxyl and ester groups. Even when we shortened the reaction time or lowered the 
reaction temperature, the undesired tetrahydroxanthones 29/31 were still observed. Thus, we 
considered that under Dieckmann cyclization conditions, para-bromide 15 may generate 
intermediate 32 in situ. Subsequent oxa-Michael reaction could convert 32 to the 
corresponding tetrahydroxanthone products.
From these results, we hypothesized that production of the desired para-bromo-
tetrahydroxanthone (cf., 30) was not favored under Dieckmann cyclization conditions. 
Therefore, we changed our strategy to prefunctionalize the tetrahydroxanthone moiety. 
However, when tetrahydroxanthone 33 was treated with chlorinating reagents such as N-
chlorophthalimide, the chloro-diketone 34 was isolated in near quantitative yield as a single 
diastereomer (Scheme 5). The anti-configuration between the chlorine and the methyl ester 
moieties was confirmed by X-ray crystal structure analysis (Figure 3).23 The high 
diastereoselectivity observed is likely due to steric repulsion between the electrophile and 
the methyl ester.
As the vinylogous acid should be the most nucleophilic moiety in the tetrahydroxanthone 
substrate, we thought that use of the enol-protected compound 35 could avoid this problem. 
After evaluating different iodination and bromination conditions, the ortho-halogenated 
product (cf., 36) was found to be dominant. We reasoned that the vinylogous acid moiety in 
the tetrahydroxanthone could be deactivated under acidic conditions. After forming the 
presumed protonated tetrahydroxanthone 37, the phenol may become the more nucleophilic 
site. As an alternative, the added TFA could protonate NIS, which may generate a more 
active iodination reagent with different selectivity. Indeed, when substrate 33 was treated 
with NIS in TFA/CH2Cl2 (Scheme 5), both para-iodo and ortho-iodo-tetrahydroxanthones 
were generated in a 1:1 ratio by crude 1H NMR analysis. The mixture was further 
methylated using trimethylsilyldiazomethane to afford para-iodide 38 and ortho-iodide 36 in 
31% and 32% isolated yields, respectively (two steps).
To access chiral, nonracemic 4,4′-linked secalonic acid A, synthesis of an enantiopure, 
monomeric tetrahydroxanthone was required. Relying on our recently developed kinetic 
resolution of the tetrahydroxanthone moiety using homobenzotetramisole (HBTM) catalyst 
39,28 we anticipated that an enantiopure para-iodide could be obtained in a similar fashion. 
However, contrary to the excellent kinetic resolution observed for ortho-iodide 36, HBTM 
catalyst 39 did not successfully catalyze acetylation of para-iodide 38 or only yielded 
moderate levels of enantioselectivity (Scheme 6). This unexpected result indicated that 
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substitution on the para-position of the tetrahydroxanthone jeopardized its reactivity with the 
HBTM catalyst system.
After the unsuccessful kinetic resolution attempts with the para-iodo tetrahydroxanthone, we 
considered that the kinetic resolution could be performed on unprotected tetrahydroxanthone 
scaffolds. Indeed, HBTM catalyst 3914b could convert 33 to the acylated product. However, 
even with a substoichiometric amount of the base (N,N-diisopropylethylamine, DIEA), the 
tetrahydroxanthone still underwent syn/anti and retro-Dieckmann rearrangement (not 
shown). As tetrahydroxanthone substrates were found to be stable under acidic conditions, 
we wondered whether base was necessary for acylation. Gratifyingly, without any base, 
kinetic resolution proceeded smoothly on tetrahydroxanthone 33 to generate (−)-33 and 
(+)-41 in excellent yield and in excellent enantiomeric excess (Scheme 6). The s factor for 
the latter reaction was above 200. For blennolide B (42) as substrate, we were concerned that 
the additional methyl group on the C ring could dramatically decrease the acylation 
reactivity of the secondary alcohol. For this case, enantioselectivities using propionic 
anhydride never exceeded 40% conversion after screening various conditions. Fortunately, 
after switching to the less hindered acylating reagent acetic anhydride, (−)-42 and the 
acylated tetrahydroxanthone (+)-43 were obtained in high yield and ee. Notably, the s factor 
observed for the unprotected blennolide B (s = 159) was even higher than that for the enol-
protected blennolide B shown previously (s = 93).14b
Using the enantioenriched tetrahydroxanthones, the para-iodo tetrahydroxanthones were 
prepared in a similar manner. With compound (−)-38 in hand (Scheme 7), we followed our 
previous sequence to protect the free phenol. However, in this case, MOM protection was 
found to be low yielding and irreproducible. Fortunately, stannylation could be cleanly 
performed on the unprotected substrate (−)-38. Remarkably, the para-iodide (−)-38 was not 
transformed to a dimeric product under our previous one-pot Suzuki dimerization 
conditions14c (Pd-SPhos-II, BPin2, K3PO4).
As there are no literature reports of stannane dimerizations with substrates containing a free 
phenol, we were concerned that a free phenol could jeopardize the dimerization step. 
Nevertheless, the resulting stannane (−)-44 was subjected to dimerization conditions. 
Applying our previously developed CuCl/air conditions to stannane (−)-44 cleanly produced 
a protodestannylated product. After further evaluation of oxidants (e.g., 
Cu(ethylhexanoate)2, Cu(OAc)2, FeCl3, Mn-(acac)3), we found that CuCl2 and ferrocenium 
tetrafluoroborate could provide the corresponding 4,4′-linked dimer (−)-45 in 40–50% 
conversion (Scheme 7). However, the yield/conversion remained inconsistent over several 
experimental trials. After further screening of additives (e.g., Na2SO4, CaCO3, NaHCO3), 
we found that trace amounts of water decreased the yield dramatically. Use of freshly dried 
stannane (−)-44 afforded the corresponding C2 symmetric dimer (−)-45 in 39% yield. 
Treatment of (−)-45 with 3 M HCl led to the formation of the deprotected 4,4′-linked 
tetrahydroxanthone dimer (+)-46 in 91% yield.
After successfully establishing access to a model 4,4′-linked dimeric tetrahydroxanthone, we 
considered that 4,4′-secalonic acid A could be synthesized in a similar manner (Scheme 8). 
Blennolide B (−)-42 was iodinated with NIS in TFA/CH2Cl2. The resulting para- and ortho-
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iodides were O-methylated to afford (−)-47 and (−)-48 (32% yield for both compounds). 
Stannylation proceeded smoothly following the previously described protocol to generate 
(−)-49. The C2 dimer (−)-50 was successfully synthesized by treating freshly dried stannane 
(−)-49 with CuCl/CuCl2. The presence of a 4,4′-linkage was further verified through a key 
HMBC correlation between C-2 and 1-OH.23 Finally, 4,4′-linked secalonic acid A (+)-51 
was obtained after acidic deprotection. In a similar manner, the Cs symmetric 
tetrahydroxanthone dimer 53 was synthesized from dimer 52, the latter obtained from the 
chiral, racemic monomer 42.23
Synthesis of 2,4′-Linked Tetrahydroxanthone Dimers
With our success in synthesizing 2,2′- and 4,4′-secalonic acids, we anticipated that we could 
also obtain the 2,4′-linked tetrahydroxanthones from heterodimerization of 2- and 4-stannyl 
tetrahydroxanthone monomers. Equimolar amounts of (−)-54 and (−)-44 were treated with 
CuCl/CuCl2 in DMA. The desired 2,4′-linked dimer (−)-56 was obtained in 32% yield 
(Scheme 9), along with 15% of the 2,2′ dimer (−)-55 and less than 5% of the 4,4′ dimer 
(−)-45. After acidic deprotection, the 2,4′-linked model tetrahydroxanthone dimer (−)-57 
was obtained in 85% yield. In a similar manner, protected 2,4′-linked secalonic acid A 
(−)-59 was constructed from (−)-58 and (−)-49 (Scheme 10). The corresponding 2,2′-linked 
dimer (−)-62 and 4,4′-linked dimer (−)-50 (not shown) were also produced in this reaction in 
around 20% and <5% yields, respectively. The 2,4′-linked dimer secalonic acid A 
(penicillixanthone A) (−)-2 was obtained smoothly after deprotection with 3 M HCl. NMR 
spectra and αD values for (−)-2 were found to be identical to those reported for the natural 
sample.5a,d
Shapeshifting Properties of 2,2′-, 2,4′-, and 4,4′-Secalonic Acids A
Burobane and co-workers9 reported that 2,2′-secalonic acids could isomerize to the 
corresponding 2,4′- and 4,4′-linked congeners in polar solvents (e.g., pyridine and CH3CN). 
Intrigued by this phenomenon, and with the synthetic 2,2′-, 2,4′-, and 4,4′-linked secalonic 
acids A in hand, we were interested to monitor this process using UPLC analysis to 
determine the ratio of products obtained on the basis of thermodynamic equilibration. We 
first considered use of DMSO as solvent for our isomerization study based on use of this 
solvent in biological assays.29 We first prepared a solution of the 4,4′-linked secalonic acid 
(+)-51 in DMSO (0.5 mg/mL) at room temperature, and the solution was monitored by 
UPLC analysis. As shown in Figure 4, we observed that the 4,4′-linked secalonic acid (+)-51 
was converted to 2,2′- (−)-1 and 2,4′-linked secalonic acids (−)-2 slowly at room 
temperature. After 13 h, the secalonic acids reached thermodynamic equilibrium. A similar 
equilibrium process was observed starting with the pure 2,2′- or 2,4′-linked secalonic acids 
A.23 The thermodynamic ratio of 2,2′-, 2,4′-, and 4,4′-secalonic acids was determined to be 
3.2:2:1 as determined by crude 1H NMR analysis.23 The isomerization process was also 
found to be faster in 10% pyridine/DMSO,23 which indicates that base can promote 
isomerization (cf., Figure 2). Forming the less sterically hindered biaryl bond may be a 
driving force for this equilibrium and the basis for favoring the 2,2′-linkage isomer in the 
equilibration process.
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Biological Studies
We explored the biological activity of the synthetic xanthones using a 48 h cancer cell 
growth inhibition assay with two renal cancer cell lines (A498, UO-31) and two colon 
cancer cell lines (Colo205 and KM12). The results are tabulated in Table 1, and dose 
response curves are provided in the Supporting Information.23 The known compounds 
secalonic acids A (−)-1, D (+)-1, and penicillixanthone (−)-2 all showed potent activity 
similar to that reported previously in L1210 leukemia cells30 and MDA-MB-435 melanoma 
and SW-620 colon cancer cells.5d The response for (+)-1 was also similar in comparison to 
the NCI 60 screen, wherein GI50 values of 550, 150, 66, and 55 nM were recorded for the 
above-mentioned cell lines.30 A major difference between the present biological assay and 
the NCI 60 screen is the use of a formazan XTT end point in contrast to the protein stain 
SRB in the NCI 60, as well as the use of higher cell densities and a 384 well format in the 
present assays. It is interesting to observe that both (−)-1 and (+)-1 have similar activities, 
which was also reported for both enantiomers of the anticancer agent simaomicin α.31
Chromone lactones 27 and 28 had no activity against any of the four cell lines at 40 µM, 
showing that the tetrahydroxanthone skeleton is necessary for cell growth inhibition. 
Comparable patterns of cell growth inhibition were seen for all three dimer linkage types, 
for example, (−)-1, (−)-2, and (+)-51, via likely interconversion and equilibration of linkage 
isomers to a mixture of 2,2′-, 2,4′-, and 4,4′-linked compounds as shown in Figure 4. While 
no specific attempt was made to control this process during bioassays, dry compounds were 
dissolved in DMSO and immediately frozen at −20 °C and then thawed the day of assay. 
While we are not able to judge the extent of equilibration that has occurred during the 48 h 
cell growth assays, the similar patterns observed for the three compounds support 
interconversion of the secalonic acid A linkage isomers in the assay. Interestingly, in our 
studies, we found that the O-methyl enol ether appears to prevent dynamic (shapeshifting) 
behavior. However, methyl enol ethers such as (−)-56 (2,4′-linked) and (−)-50 (4,4′-linked) 
were found to have reduced biological activities, while the protected compounds (−)-62 and 
(+)-63 (2,2′-linked) maintained modest bioactivities. Nevertheless, all methyl-protected 
substrates have reduced bioactivities in comparison to the unprotected dimeric 
tetrahydroxanthones, which leads us to believe that the tetrahydroxanthone moiety is crucial 
for their cytotoxicity. It is also noteworthy that compounds such as (−)-61 and (−)-62 (Figure 
5) appear to have different patterns of cell growth inhibition from the others, perhaps 
indicating a different mode of action. Of the tetrahydroxanthones, only the rugulotrosin 
derivative (−)-6014c was found to be inactive against all cell lines tested. Moreover, 
compound (+)-46 has reduced cytotoxicity in comparison to (+)-51, which contains an 
additional methyl group on the tetrahydroxanthone C ring. A similar pattern also was 
observed for compounds (−)-57 and (−)-2. These results indicate that the methyl group on 
the C ring may provide a hydrophobic site, which is crucial for cytotoxicity. These 
conclusions about selectivity and potency are preliminary, and a more meaningful analysis 
will require testing in the full NCI 60 screen.
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CONCLUSION
We have developed a copper-mediated aryl stannane coupling protocol to access chromone 
lactone dimers as well as 4,4′- and 2,4′-linked dimeric tetrahydroxanthones. A highly 
selective kinetic resolution was performed on an unprotected tetrahydroxanthone scaffold to 
enable access to chiral, nonracemic monomers. Asymmetric syntheses of 2,4′-linked 
(penicillixanthone A) and 4,4′-linked secalonic acids A and their analogues have been 
achieved. Our investigation also led to the discovery of a gold(III)-catalyzed para-
bromination of a chromone lactone substrate. With a varied linkage series of secalonic acids 
A, the “shapeshifting” properties were evaluated and monitored by UPLC analysis. Initial 
biological studies of secalonic acid A analogues revealed that the dimeric 
tetrahydroxanthone moiety was crucial for cytotoxicity against select cancer cells and that 
isomerization of the biaryl linkage likely occurs during the cell-based assays. Further 
biological studies of secalonic acid derivatives, as well as the chemistry of the secalonic acid 
core structure, are ongoing and will be reported in due course.
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Figure 1. 
2,2′-Linked and related 2,4′- and 4,4′-linked secalonic acids.
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Figure 2. 
Shapeshifting, dynamic equilibration of the parnafungins.
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Figure 3. 
X-ray crystal structure of chlorinated tetrahydroxanthone 34.
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Figure 4. 
Equilibration of 4,4′-linked secalonic acid A in DMSO.
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Figure 5. 
Structure of additional dimeric tetrahydroxanthones investigated.
Qin et al. Page 15
J Am Chem Soc. Author manuscript; available in PMC 2016 December 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Scheme 1. 
Bromination of a Chromone Lactone Substrate
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Scheme 2. 
Possible Mechanisms for para-Bromination
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Scheme 3. 
Synthesis of a Chiral, Racemic 4,4′-Linked Chromone Lactone
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Scheme 4. 
Dieckmann Cyclization of Brominated Tetrahydroxanthones
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Scheme 5. 
Synthesis of a para-Iodo Tetrahydroxanthone
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Scheme 6. 
Kinetic Resolution of an Unprotected Tetrahydroxanthone Substrate
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Scheme 7. 
Asymmetric Synthesis of a Model 4,4′-Linked Tetrahydroxanthone Dimer
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Scheme 8. 
Asymmetric Synthesis of a 4,4′-Linked Secalonic Acid A
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Scheme 9. 
Asymmetric Synthesis of Model 2,4′-Linked Tetrahydroxanthone Dimer
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Scheme 10. 
Asymmetric Synthesis of a 2,4′-Linked Secalonic Acid A (Penicillixanthone A)
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